Yahoo · Aug 21, 2026
Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening
With US procedure growth slowing and the shares well below their high, the operating margin has widened in each of the last three years.
NYSE · ZBH
Zimmer Biomet Holdings, Inc.
Healthcare · Medical - Devices
$100.91
Down-$0.70 (-0.69%)
Updated Aug 31, 2026, 2:17 PM
SID Score
6.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 18.32B
- P/E ratio
- 22.74
- Dividend yield
- 0.95%
- 52-week range
- $79.12 – $102.12
- Volume
- 1.19M
- Avg. volume
- 1.84M
Price performance
ZBH price history
1M range · 20 trading sessions · Daily adjusted prices
ZBH closed at $100.91 after 20 trading sessions, up 4.05% for the selected period.
- Last close
- $100.91
- Period change
- +4.05%
- Period low
- $95.81
- Period high
- $101.38
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $99.61 | $101.32 | $99.245 | $100.91 | 1.19M |
| Aug 27, 2026 | $99.93 | $101.28 | $99.21 | $99.48 | 1.35M |
| Aug 26, 2026 | $99.52 | $101.98 | $99.20 | $101.38 | 1.35M |
| Aug 25, 2026 | $100.14 | $100.87 | $99.28 | $100.24 | 1.27M |
| Aug 24, 2026 | $101.32 | $102.12 | $100.69 | $100.98 | 1.5M |
| Aug 21, 2026 | $98.67 | $101.15 | $98.67 | $100.98 | 1.16M |
| Aug 20, 2026 | $100.01 | $101.63 | $98.97 | $98.97 | 1.33M |
| Aug 19, 2026 | $98.72 | $101.95 | $98.09 | $100.74 | 1.5M |
| Aug 18, 2026 | $99.58 | $100.38 | $98.2701 | $99.15 | 1.21M |
| Aug 17, 2026 | $99.78 | $100.145 | $97.87 | $98.20 | 1.75M |
| Aug 14, 2026 | $99.59 | $101.155 | $98.97 | $100.65 | 2.15M |
| Aug 13, 2026 | $98.42 | $100.06 | $97.615 | $99.57 | 2.62M |
| Aug 12, 2026 | $95.69 | $97.94 | $94.28 | $97.89 | 2.73M |
| Aug 11, 2026 | $97.12 | $98.11 | $96.24 | $97.23 | 2.73M |
| Aug 10, 2026 | $96.66 | $97.845 | $95.4601 | $97.78 | 3.28M |
| Aug 7, 2026 | $96.58 | $96.89 | $94.88 | $96.55 | 2.19M |
| Aug 6, 2026 | $98.80 | $99.91 | $95.67 | $97.19 | 3M |
| Aug 5, 2026 | $101.00 | $101.80 | $96.78 | $98.16 | 5.48M |
| Aug 4, 2026 | $95.49 | $96.44 | $94.77 | $95.81 | 3.55M |
| Aug 3, 2026 | $95.57 | $97.02 | $95.47 | $96.98 | 2.25M |
Latest ZBH news
The latest Smart Investors Daily articles mentioning ZBH.
Stock researchCompany · Overview
ZBH research
Overview
Company profile and research snapshot.
Company profile
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $112.29
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Hold | — |
| Aug 7, 2026 | Truist Securities | Hold | — |
| Aug 6, 2026 | Bernstein | Market Perform | — |
| Aug 6, 2026 | Stifel | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 20, 2026
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.
Yahoo · Aug 20, 2026
Zimmer Biomet (ZBH) Stock Still Looks Discounted After a 28% Five Year Slide
Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...
Yahoo · Aug 18, 2026
Is ISRG's Software Strategy Becoming as Important as Its Robots?
ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
